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Abstract
Severe combined immunodeficiency (SCID) has a diverse genetic aetiology, where a 
clinical phenotype, caused by single and/or multiple gene variants, can give rise to 
multiple presentations. The advent of next-generation sequencing (NGS) has recently 
enabled rapid identification of the molecular aetiology of SCID, which is crucial for 
prognosis and treatment strategies. We sought to identify the genetic aetiology of 
various phenotypes of SCIDs and assessed both clinical and immunologic character-
istics associated with gene variants. An amplicon-based targeted NGS panel, which 
contained 18 most common SCID-related genes, was contumely made to screen the 
patients (n = 38) with typical SCID, atypical SCID or OMENN syndrome. Allelic seg-
regations were confirmed for the detected gene variants within the families. In total, 
24 disease-causing variants (17 known and 7 novel) were identified in 23 patients in 9 
2  |     FIRTINA eT Al.
1  | INTRODUC TION
Primary immunodeficiencies (PIDs) are a group of disorders that can 
present with a wide spectrum of manifestations, including an undue 
susceptibility to infections, severe allergies, autoimmunity, malignancy 
and excessive inflammation (Notarangelo, 2010). Severe combined 
immunodeficiency (SCID) represents the most severe form of PIDs, 
which is caused by monogenic (mostly autosomal-recessive or X-linked) 
defects that impair the development and/or function of lymphocytes 
(Parvaneh, Casanova, Notarangelo, & Conley, 2013). Typical SCIDs are 
defined by a complete loss of T lymphocytes with or without accom-
panying defects of the B and/or NK cells. Occasionally, hypomorphic 
variants of the genes whose null mutations are responsible from the 
classical SCID phenotypes can lead to a disorder where T-cell differ-
entiation is partially maintained, referred to as “atypical SCID” (Fischer, 
Notarangelo, Neven, Cavazzana, & Puck, 2015; Shearer et al., 2014).
If remained untreated, SCID is a deadly disease, with most fatal-
ities occurring within the first year of life. SCID patients can be di-
agnosed early with detailed clinical evaluation, immunophenotyping 
and molecular analysis. Early diagnosis is the key to the successful 
management of SCID, whereas failure to diagnose in time will lead to 
delay in hematopoietic stem cell transplantation (HSCT).
Incidence of SCID was found to be 1/58,000 in the United States, 
quite higher than once thought (1/100,000) based on retrospective 
clinical diagnoses (Kwan et al., 2014). Further, despite the lack of robust 
epidemiologic data, it is expected that the incidence of SCID would be 
even higher among countries with high consanguinity rates like Turkey 
(Kilic et al., 2013; Yorulmaz, Artaç, Kara, Keleş, & Reisli, 2008).
To date, mutations in more than 30 genes are related to SCID 
pathogenesis, caused by different mechanisms that affect various 
steps in T-cell development. Apoptosis of hematopoietic progenitor 
cells is observed in reticular dysgenesis disease (AK2) and in ade-
nosine deaminase (ADA) enzyme deficiency. Defects of IL2RG, JAK-3 
and IL7RA genes cause impairments in cytokine-induced signalling in 
T cells and NK progenitor cells. TCR complex defects (CD45, CD3D, 
CD3E and CD3Z) are critical for thymus development and mutations 
lead to the absence of thymus and T cells. In addition, mutations 
in V(D)J rearrangement and DNA repair mechanisms (RAG-1, RAG-2, 
NHEJ, DCLRE1C and PRKDC) genes block T- and B-cell development. 
(Cirillo et al., 2019; Fischer et al., 2015; Notarangelo, 2010; Rivers & 
Gaspar, 2015; Schumacher & Notarangelo, 2002).
Complex phenotypes and an increasing number of responsible 
genes make the genetic diagnosis difficult (Picard et al., 2015). Whole 
exome and genome sequencing (WES and WGS) are powerful tools 
to identify novel disease-related genes/pathways, whereas targeted 
sequencing approaches have been used with success in the identifi-
cation of deleterious gene variants on known genes as well as deter-
mining the genotype–phenotype correlation for diagnostic purposes 
(Fang, Abolhassani, Lim, Zhang, & Hammarstrom, 2016). The diverse 
presentations of PIDs and variable phenotype–genotype correlations 
require a multifactorial approach for the accurate and timely diagnosis 
of these potentially fatal conditions. Moreover, targeted next-gener-
ation panels have offered a cost-effective and rapid diagnostic tool 
for clinical use. Choosing the right enrichment strategies in the cus-
tom-designed targeted panels is critical for accurate and high-quality 
sequencing reads (Stoddard, Niemela, Fleisher, & Rosenzweig, 2014). 
Since probe-based targeted sequencing has some limitations, mainly 
due to the inability to avoid pseudogenes and genomic repeats, a com-
bination of PCR and probe enrichment strategies has been developed 
(Yu et al., 2016). The requirement for expanding target size leading to a 
harder optimization process and higher primer cost, PCR-based (ampli-
con) enrichment methods still have the best sequencing specificity (De 
Wilde et al., 2014; Mamanova et al., 2010).
This study aimed to determine the genetic background of SCID 
by using a custom-designed amplicon-sequencing panel for SCID 
patients. In this manuscript by using the custom-made sequencing 
panel, we were able to identify and confirm the previously known 
and novel disease-causing variants with high accuracy confirm the 
familial segregations and evaluated the genotype–phenotype cor-
relations for the novel variants in SCID.
2  | MATERIAL S AND METHODS
2.1 | Patients
We studied 40 patients with SCID, 38 of whom were newly diag-
nosed at the time of study inclusion (21 boys and 17 girls) whereas 
different SCID genes: RAG1 (n = 5), RAG2 (n = 2), ADA (n = 3), DCLRE1C (n = 2), NHEJ1 
(n = 2), CD3E (n = 2), IL2RG (n = 3), JAK3 (n = 4) and IL7R (n = 1). The overall success 
rate of our custom-made NGS panel was 60% (39.3% for NK+ SCID and 100% for NK− 
SCID). Incidence of autosomal-recessive inherited genes is more frequently found in 
our cohort than the previously reported populations probably due to the high consan-
guineous marriages in Turkey. In conclusion, the custom-made sequencing panel was 
able to identify and confirm the previously known and novel disease-causing variants 
with high accuracy.
K E Y W O R D S
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two were previously known cases. Patients were classified as typical 
SCID (n = 36), atypical SCID (n = 3) or Omenn Syndrome (n = 1) based 
on the diagnostic criteria recommended by the European Society 
for Immunodeficiencies (ESID, ESID.org, ESID Registry—Working 
Definitions for Clinical Diagnosis of PID). A diagnosis of typical SCID 
was made in a child who presents with suggestive clinical findings in 
the first year of life, plus 2 out of 4 T-cell criteria is satisfied; low or 
absent CD3 or CD4 or CD8 T cells, reduced naive CD4 and/or CD8 
T cells, elevated g/d T cells, reduced or absent proliferation to mito-
gen or TCR (T-cell receptor) stimulation. Clinical criteria for atypical 
SCID included identification of a mutation in a SCID-causing gene, 
plus > 100 T cells/μl, plus absence of characteristic SCID-associated 
infections in the first year of life, plus lack of clinical criteria for 
OMENN syndrome. Omenn syndrome was diagnosed if he/she 
presents with desquamating erythroderma in the first year of life, 
plus presence of one or more of the following findings; lymphopro-
liferation, failure to thrive, chronic diarrhoea, recurrent pneumonia 
findings plus eosinophilia or elevated IgE, plus T-cell deficiency (low 
naive cells, reduced proliferation and oligoclonality), plus no mater-
nal engraftment, plus exclusion of HIV infection.
Our cohort included six patients with T− B+ NK+ phenotype, 
ten patients with T− B+ NK+ phenotype, five patients with T- B- 
NK- phenotype and nineteen T−B−NK+ patients. Median age was 
6 months (min 1.5 months–max 13 years) except one 30-year-old 
atypical SCID patient. Median ALC was 1,300 (min 40–max 7,300). 
Seventy-seven per cent (31 in 40) of the families of SCID cases were 
consanguineous. Maternal engraftment was checked in all atypical 
SCID patients, and no maternal engraftment was seen. Development 
delay was seen in 60% of our patients. 24 patients underwent HSCT, 
and only four of them deceased.
Detailed clinical features of the patients were given at Table 1. 
This study was approved by the ethical board of Istanbul Medical 
Faculty (2015/492), and written informed consents were obtained 
from all parents or legal representatives.
2.2 | Amplicon-based targeted next-
generation sequencing
The NGS SCID panel was custom designed by SmartChip-TE tech-
nology (WaferGen). It consists of 432 amplicons covering the cod-
ing regions, promoters and untranslated region (UTR) sites of 18 
most seen SCID-related genes (IL2RG, JAK3, IL7RA, PTPRC, CD3D, 
CD3E, CD3Z, CORO1A, DCLRE1C, PRKCD, AK2, ADA, RAG1, RAG2, 
XLF/NHEJ1, LIG4, PNP and ZBTB24) with a target size of 167,092 
base pair. Candidate genes were selected based on the 2014 IUIS 
(International Union of Immunological Societies) SCID classification 
(Al-Herz et al., 2014). TLEN (observed Template LENgth) median was 
386 with the minimum 250 and maximum 450 base pair. Chip capac-
ity was 12 samples per run. Genomic DNA was isolated from the 
peripheral blood mononuclear cells of the patients and family mem-
bers by using QIAmp DNA Blood Mini Kit (Qiagen). Quantity and 
quality of DNA were determined by using Nanodrop 2000 (Thermo 
Fisher Scientific). Enrichment of target regions was performed by 
Seq-Ready™ TE Multisample NanoDispenser according to manufac-
turers’ protocol. Quantification of all libraries was done by Quant-iT 
PicoGreen dsDNA Assay Kit with LC480 (Roche Diagnostics). 
Samples were sequenced with Illumina Miseq reagent V2 kit on 
Illumina Miseq (Illumina) sequencer. Two SCID patients with four 
known variants (SC01 with RAG1 and SC31 with ADA compound 
heterozygosity) were used as control samples to validate our tar-
geted sequencing approach and the pipeline of data analysis. Variant 
validation in patients and allelic segregation analysis in families were 
performed using Sanger sequencing.
2.3 | Data analysis and functional interpretation
Mapping to a reference genome (hg19), variant calling and annota-
tion were performed by using two different programs; SEQ 2.8.2 
(Genomize) and Seqnext (JSI Medical systems GmbH). To predict 
the severity of variants, open source programs such as SIFT (Kumar, 
Henikoff, & Ng, 2009), Polyphen (Adzhubei et al., 2010), Variant 
effect predictor (VEP) (McLaren et al., 2016), Mutation Taster 
(Schwarz, Cooper, Schuelke, & Seelow, 2014) and CADD (Combined 
Annotation Dependent Depletion) (Kircher et al., 2014) were used. 
All the variants were classified by the standards and guidelines 
for the clinical interpretation of sequence variants with respect to 
human diseases according to ACMG/AMP 2015 guideline based on 
28 criteria (Richards et al., 2015).
Multiple alignments were generated by UCSC. The available 
public databases including dbSNP database (https://www.ncbi.nlm.
nih.gov/SNP/), 1,000 Genomes Project samples (http://www.1000g 
enomes.org/), the Exome Variant Server (ESP) (http://evs.gs.washi 
ngton.edu/EVS/), The Human Gene Mutation Database (HGMD) 
(http://www.hgmd.cf.ac.uk/ac/index.php) database, the Exome 
Aggregation Consortium (ExAC) (http://exac.broad insti tute.org/) 
and GNOMAD (https://gnomad.broad insti tute.org) were used for 
frequency data and to predict the functional impact of the varia-
tions. The Rockefeller University in house exome databases (3,000 
PID and healthy samples) were screened for novel variants. CLC 
Main workbench 3.6.1 (Denmark) was used for Sanger Sequencing 
data analysis.
3  | RESULTS
3.1 | Target enrichment performance and diagnostic 
efficiency
All coding regions, 5′- and 3′-UTR parts and flanking intronic regions 
of 18 genes associated with SCID phenotype were amplified with 
432 amplicons in the targeted NGS panel. Although the designed 
primer pairs were aimed to cover all regions of interest (ROI) parts, 
the observed mean of targeted regions with at least 20X cover-
age was 96.35% and for the coding regions observed coverage was 
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97.89%. In 11 out of 18 genes, 100% coverage was achieved for all 
targeted regions, except CORO1A (exons 1, 2 and 11), ADA (exon 
1), JAK3 (exon 1) and IL7R (exon 7) genes. Although the coverage of 
PRKCD, LIG4 and ZBTB24 genes were below 100%, all the uncovered 
regions were among the noncoding sequences and coding regions of 
these genes were fully covered (Table S1).
TA B L E  1   Clinical findings of SCID patients
Patient Gene Defect SCID phenotype Age (year) Gen.
ALC 
(lymphocytes/µl)
Dev. 
Del. Cons. HSCT Outcome
SC31 ADA T-B-NK- 3 M 2,200 No No Yes Alive
SC42 ADA T-B-NK- 1 F 300 Yes Yes No Alive
SC44 ADA T-B-NK- 6 months F 40 No Yes Yes Alive
SC38 ADA T-B-NK- 4 months M 300 Yes Yes Yes Alive
SC21 CD3E T-B+NK+ 3 months F 1,450 No Yes No Deceased
SC22 CD3E T-B+NK+ 2 months M 1,900 Yes Yes Yes Alive
SC04 DCLRE1C T-B-NK+ 4 months M 1,600 Yes Yes Yes Deceased
SC37 DCLRE1C T-B-NK+ 4 months F 2,400 Yes Yes Yes Alive
SC17 IL2RG T-B+NK- 3 months M 700 No No No Deceased
SC34 IL2RG Atypical T-B-NK- 30 M 1,200 Yes No No Alive
SC43 IL2RG T-B+NK- 3 months M 1,650 Yes No Yes Alive
SC36 IL7R T-B+NK+ 11 months F 2,400 No Yes Yes Alive
SC09 JAK3 T-B+NK- 6 months M 700 Yes Yes No Deceased
SC20 JAK3 T-B+NK- 6 months F 400 Yes Yes No Deceased
SC29 JAK3 T-B+NK- 1 M 2,600 Yes Yes Yes Alive
SC39 JAK3 T-B+NK- 2 F 2,200 No Yes Yes Alive
SC19 NHEJ1 T-B-NK+ 18 months F 2,410 Yes Yes Yes Alive
SC49 NHEJ1 T-B-NK+ 5.5 F 400 Yes Yes Yes Alive
SC01 RAG1 Atypical T-B-NK+ 13 F 700 Yes Yes Yes Alive
SC13 RAG1 T-B-NK+ 3 M 2,850 No No No Deceased
SC15 RAG1 T-B-NK+OMENN 3 F 7,300 Yes Yes No Deceased
SC41 RAG1 T-B-NK+ 3 months F 1,330 No Yes Yes Deceased
SC47 RAG1 T-B-NK+ 4 months F 1,000 Yes Yes Yes Alive
SC16 RAG2 T-B-NK+ 3 months M 700 No Yes Yes Alive
SC24 RAG2 T-B-NK+ 9 months M 1,180 Yes Yes Yes Alive
SC02 Not Detected Atypical T-B+NK+ 1.5 M 2,400 Yes No No Alive
SC03 Not Detected T-B-NK+ 3 M 2,900 Yes Yes Yes Alive
SC05 Not Detected T-B-NK+ 4 months F 500 Yes Yes No Deceased
SC06 Not Detected T-B+NK+ 1.5 months F 1,600 Yes No No Alive
SC07 Not Detected T-B+NK+ 1 M 2,700 No No No Alive
SC08 Not Detected T-B-NK+ 1.5 months M 1,300 Yes Yes No Deceased
SC10 Not Detected T-B+NK+ 1 F 1,220 Yes Yes Yes Deceased
SC14 Not Detected T-B-NK+ 3 months F 400 Yes Yes Yes Alive
SC18 Not Detected T-B+NK+ 1 M 500 No No Yes Deceased
SC25 Not Detected T-B-NK+ 1 M 500 No Yes No Alive
SC32 Not Detected T-B+NK+ 2 months M 2,400 Yes Yes No Deceased
SC40 Not Detected T-B-NK+ 2 months F 1,100 No Yes Yes Alive
SC45 Not Detected T-B+NK+ 10 months M 1,300 No Yes No Alive
SC46 Not Detected T-B-NK+ 6 months F 1,540 No Yes Yes Alive
SC48 Not Detected T-B-NK+ 4 months M 770 No Yes Yes Alive
Abbreviations: ALC, Absolute lymphocyte count; Cons, Consanguinity; Dev. Del, Development Delay; F, Female; Gen, Gender; HSCT, Hematopoietic 
stem cell transplantation; M, Male; Mo, Month.
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3.2 | Identified genetic variations
The accuracy of detecting variants was evaluated by using two pre-
viously diagnosed SCID samples (SC01 and SC13) with four known 
genetic variants, and all were identified and confirmed successfully. 
The success rate of our custom-made NGS panel was 60% for the 
SCID cohort with the detection of 24 disease-causing variants in 23 
of 38 SCID patients. The variants (Table 2, Figure S1) were found in 
RAG1 (n = 5, 13%), RAG2 (n = 2, 5.2%), ADA (n = 3, 7.8%), DCLRE1C 
(n = 2, 5.2%), NHEJ1 (n = 2, 5.2%), CD3E (n = 2, 5.2%), IL2RG (n = 3, 
7.8%), JAK3 (n = 4, 10.5%) and IL7R (n = 1, 2.6%). Among these, sev-
enteen variants have been previously reported, whereas seven vari-
ants were novel. All the identified variants were confirmed by Sanger 
sequencing in the patients. We were able to show the allelic segrega-
tion by Sanger sequencing in all families except in four (SC04, SC16, 
SC17 and SC20) patient's families due to the lack of parental DNA.
3.2.1 | Variants in T-B-NK+ patients
Six patients with T−B−NK+ phenotype and OMENN syndrome were 
found to harbour disease-causing variants in RAG1 and RAG2 genes. Five 
of those variants were previously described (A444V, G392E, R159C, 
R776W and Y589*) whereas we identified a novel RAG2 c.1442A>G 
p.(H481R) variant in patient SC24 (Figure 1a). H481R variant locates 
at the highly conserved plant homeodomain (PHD) finger of RAG2 pro-
tein. SC24 is nine-year-old boy had growth retardation and clinically 
presented with anaemia, lymphopenia, malabsorption and pneumonia.
One patient (SC13) was found compound heterozygous for two 
different RAG1 variants, a known variant c.1331C>T (rs199474685) 
and a novel frameshift variant c.736_736delG:p.(A246Pfs*18) that 
were later confirmed as compound heterozygous in an in vitro fertil-
ization (IVF) centre (data not shown). SC13 is a CMV-positive, T−B−
NK+, 3-year-old boy who was suffered from recurrent bronchiolitis, 
lower aspiratory tract infections diarrhoea and oral moniliasis.
Two patients with T−B−NK+ phenotype were found to have 
homozygous DCLRE1C variants; SC37 had a novel frameshift vari-
ant c.716_716delC p.(P239Lfs*46) and SC04 had a novel nonsense 
variant c.560T>G, p.(L187*) (Figure 1b,c). The c.716_716delC variant 
is located in exon 9 leading to a frameshift and a premature stop 
codon, and the other c.560T>G variant is in exon 8 and creates an 
early stop codon. Both variations are predicted as disease causing 
and pathogenic. SC37 is a 4-month-old girl suffered from recurrent 
pneumonia (twice a month), lymphopenia and absence of the thymic 
shadow. She was transplanted and still alive. SC04 is 4-month-old 
boy who had similar clinical findings and family history, but he died 
after transplantation.
3.2.2 | Variants in T−B−NK− patients
In three patients who were presented with a T−B−NK− phenotype, 
ADA variants (R101Q, G20R and IVS5 −2 as) were identified. A novel 
splice donor variant c.478+2T>C (IVS5 −2 as) was found in SC38 
(Figure 1d). He is 4-month-old and suffered for frequent respiratory 
infections, conjunctivitis and growth retardation, and no ADA en-
zyme activity was detected. After transplantation, he is still alive. 
Surprisingly, a 30-year-old male patient (SC34), who is diagnosed 
as T-B-NK- atypical SCID phenotype, was harboured a promoter 
variant c.-105C>T on IL2RG gene. The onset of clinical symptoms 
was started at the age of two, with recurrent otitis media, upper 
respiratory tract infections and severe pneumonia. He underwent 
right lower lobectomy when he was 13. However, the patient has 
experienced recurrent pneumonia after surgery. He is still receiving 
Intravenous Immunoglobulin (IVIG) therapy.
3.2.3 | Variants in T-B+NK- patients
JAK3 gene variants (E694*, R775H, R771* and W623*) were found in 
four SCID patients. The c.2080G>T p.(E694*) was a novel nonsense 
variant and was predicted as pathogenic/disease causing (Figure 1e). 
SC20 is a 6-month-old girl presented with bronchiectasis, moniliasis, 
candidiasis, RSV-positive and growth retardation. She died without 
transplantation. This variant is in a highly conserved JH2 domain 
of JAK3 protein. The second JAK3 variant c.2324G>A p.(R775H) 
(Figure 1f) was shown in only one ovarian cancer patient previously 
but this is the first time for this variant to be shown in an immuno-
deficiency patient.
In addition, two known hemizygous variants (c.865C>T,p.R289* 
and c.115G>A,p.D39N) were detected in the IL2RG gene in patients 
SC17 and SC43 (DiSanto, Dautry-Varsat, Certain, Fischer, & de Saint 
Basile, 1994).
3.2.4 | Variants in (T-B+NK+) patients
A known nonsense variant c.616C>T p.(R206*) was found in the 
IL7R gene in SC36. Two-second degree cousins (SC19 and SC49) 
were found homozygous for a c.532C>T, p.(R178*) mutation in 
the NHEJ1 gene which was previously associated with Cernunnos 
deficiency.
4  | DISCUSSION
The genetic aetiology underlying PIDs are diverse, with the number 
of responsible genes increasing each year. Early and accurate diag-
nosis has enabled major advances in the care of infants with PID, 
in particular SCID, including better outcomes of HSCT or alterna-
tive options such as enzyme replacement treatment or gene therapy 
(Rivers & Gaspar, 2015). Moreover, it provides additional informa-
tion to improve the prognosis, guide genetic counselling and prena-
tal diagnosis (Notarangelo, 2010). However, many patients do not 
receive a molecular diagnosis despite extensive clinical and immuno-
logic studies, mainly due to the large number of genes that can cause 
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similar phenotypes. The recent advent of next-generation sequenc-
ing technologies and its applications in PID research has accelerated 
the discovery of novel genes that are associated with PIDs (Cifaldi 
et al., 2019; Gallo et al., 2016). Targeted NGS panels have been com-
monly engaged in the clinical laboratories as powerful tools that 
aid molecular diagnosis by virtue of their capacity to investigate 
multiple genes simultaneously (Raje et al., 2014), with a reported 
success rate of 25%–40% among studies (Al-Mousa et al., 2016; 
Erman et al., 2017; Fang et al., 2016; Nijman et al., 2014; Stoddard 
et al., 2014; Yu et al., 2016).
In this study, we have developed a SCID-NGS panel for rapid 
identification of disease-causing variants in patients with a clinical 
diagnosis of SCID in Turkey and provided a success rate of 60%, with 
24 disease-causing variants identified among 23 out of 38 SCID pa-
tients. Most common variants were found on the nine SCID-related 
genes: RAG1, RAG2, ADA, DCLRE1C, NHEJ1, CD3E, IL2RG, JAK3 
and IL7R. In addition, twenty-nine per cent (7/24) of identified dis-
ease-causing variants were novel in our study. In a previous study 
from Turkey, Erman et al screened 19 SCID patients from Turkey 
with a targeted NGS panel that contains 356 PID-related gene and 
showed the genetic alterations in six patients (33%) in RAG1, JAK3 
and IL2RG genes (Erman et al., 2017). Here, we generated an NGS 
panel for SCID, and despite to a small number of genes (18 genes), 
we had a better success rate in our study. This might be due to the 
large number of patients, stricter patient enrolment strategies and 
specific bioinformatics analysis pipelines.
The SCIDX1 patients with IL2RG deficiency are the largest group 
in the populations with low-consanguinity rates like European or far 
east countries (Fischer et al., 2015; Luk et al., 2017), but we found 
RAG1/2 deficiency (47%) which leads to T-B-NK+ phenotype is the 
most common group in our Turkish SCID cohort. Due to the high 
consanguineous marriage rates in our country, autosomal-recessive 
inherited genes might be the most effected genes among the SCID 
patients in our cohort. Families with more than one child and higher 
consanguinity rates increase the incidence of monogenic diseases 
such as SCID in Turkey. Previously, we described a novel frameshift 
variant in CD3E gene (Firtina et al., 2017) and in two unrelated pa-
tients in the same region of Turkey, which showed that consanguin-
eous marriages or isolated populations could cause a high incidence 
of very rare genotypes in certain regions.
All the T-B-NK- SCID patients were mutated on ADA and IL2RG 
genes. Among previously known SCID-related variants, a novel 
splice-site c.478+2T>C variant on ADA gene (SC38), leading to abro-
gated enzyme activity, has been identified. ADA deficiency is one of 
the most prevalent forms of SCID, which together with reticular dys-
genesis (caused by AK2 variants) causes a T-B-NK- SCID phenotype 
in the majority of the patients (Kohn & Gaspar, 2017). The promoter 
variant detected in the IL2RG gene (c.105C>T) in our cohort (SC34) 
with an atypical SCID phenotype (T-B-NK-) was previously reported 
in a case, which had been clinically diagnosed with CVID and NK-
cell lymphopenia (Chandra et al., 2016). IL2RG gene is responsible 
for SCIDX1 and resulted with the absence of T and NK cells with 
F I G U R E  1   Familial segregation of the novel variants in RAG2 (1a), DCLRE1C (b,c), ADA (1D) and JAK3 (e,f) genes in our cohort. Filled 
black rectangles show affected individuals and double horizontal lines indicate consanguinity. Genotype of individual family members is 
shown next to the representative symbols in each pedigree (a-f). Evolutionary comparison of the protein sequences for the variations with 
their orthologous counterparts in 18 vertebrates is shown in the bottom of each pedigree. The altered residues are highlighted by a black 
rectangle
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normal B-cell numbers (Allenspach, Rawlings, & Scharenberg, 1993). 
However, studies showed that deleterious IL2RG variants could lead 
to variable phenotypes (Mou et al., 2017) as illustrated by this case 
with no B and T cells (Jones et al., 1997). All patients with T-B+NK− 
phenotype were found mutated in JAK3 and IL2RG genes. Two novel 
JAK3 variants (p.E694* and p.R775H) were found to be located at 
the pseudokinase domain, which is essential for JAK3 function to 
regulate its catalytic activity. Cheng et al. have previously reported 
that the patients with mutations in the JAK3 pseudokinase domain 
have protein expression but the regulation of the kinase activity 
is disrupted (Chen et al., 2000). Deleterious mutations in the gene 
DCLRE1C that encodes the ARTEMIS protein have been associated 
with a wide range of PIDs including the T−B−NK+ SCID, radiosensi-
tive OMENN syndrome or Hyper IgM syndrome (Volk et al., 2015). 
Here, we found two novel DCLRE1C variants (L187* and P239Lfs*46) 
in two infant T−B−NK+ patients. All DCLRE1C variants that were de-
tected in this study were novel and are predicted to cause the loss 
of ARTEMIS protein, which leads to severe combined immunodefi-
ciency phenotype.
Molecular analysis of DCLRE1C gene was difficult to define 
due to homologous recombination of the wild-type DCLRE1C 
gene with a pseudogene located 61.2 kb 5’ to the DCLRE1C 
start codon (Pannicke et al., 2010). p.L187* is located in exon 8 
which shows high sequence similarities with the pseudogene of 
DCLRE1C. Single-plex PCR-based methods give flexibility to avoid 
pseudogenes by designing specific primers and enhance the suc-
cess of variant detection. Our custom-made panel successfully 
identified a variant in a region that has high sequence similarities 
with pseudogenes.
The majority of our cohort was comprised of NK-positive 
(T-B-NK+; n = 18 and T−B+NK+; n = 10) SCID patients and screening 
the most common 18 SCID-related genes by our custom-designed 
panel can identify the disease-causing variants in almost 40% of 
T−B−NK+patients. On the other hand, all the patients with NK-cell 
lymphopenia (NK cells negative) were found mutated for the genes 
in our custom panel. These findings showed that NK-positive pa-
tients have a complex background with undiscovered mechanisms/
genes or in combination with different syndromes.
NGS-based technologies are the best options for diseases with 
genetic heterogeneity. An advantage of disease-specific panels, 
when compared to WES, would be the lack of a need for filtering 
out unnecessarily high numbers of irrelevant gene variants that 
is inherent to the latter strategies. On the other hand, immune 
deficiencies are accompanying to many genetic disorders that can 
be difficult to diagnose and discriminate in the early years of life 
and needs larger screening panels. Identified variants were found 
on the fifty per cent of analysed genes, and later studies showed 
the mutations of common syndrome genes that were excluded. 
These findings give the idea that reset of the targeted panels ac-
cording to the mutation ratios in the individual populations and 
the most common syndromic genes should also be added. WES 
or WGS studies with the possible inclusion of the parents and 
unaffected siblings could be reserved for the unsolved or more 
complex cases.
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